A venture capital firm founded in 2002 invests solely in life sciences companies and is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 70% on Asia and 30% on global deals and is currently seeking new opportunities.
Within life sciences, the firm is most interested in biotech therapeutics including biologics, small molecules, and drug formation. The firm considers all indications with a focus on neurodegeneration and psychology. The firm prefers assets ranging from preclinical to phase II. Historically the firm has invested in medical technology, agricultural biotech, and biotech R&D services, but will consider these sectors with less interest.
The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with investee companies closely.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org